Rheumatoid arthritis: A female challenge

Women's Health

Volumn 4, Issue 2, 2008, Pages 195-201

  Gerosa, M ^a   De Angelis, V ^a   Riboldi, P ^a   Meroni, Pier Luigi ^b  

^a Ospedale San Luca   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Autoimmunity; Female gender; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ANDROSTANOLONE; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CONTRACEPTIVE AGENT; CYCLOSPORIN; CYTOKINE; ESTRADIOL; ESTROGEN; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHOLIPID ANTIBODY; PRASTERONE; PROLACTIN; RITUXIMAB; SEX HORMONE; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; BREAST FEEDING; CARDIOVASCULAR RISK; CONTRACEPTION; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HORMONAL CONTRACEPTION; HORMONAL REGULATION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; NONHUMAN; PATHOPHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; PREGNANCY; PREVALENCE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH2 CELL;

ANIMALS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; FEMALE; GONADAL STEROID HORMONES; HUMANS; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE AGENTS; OSTEOPOROSIS; PREGNANCY;

EID: 41949130259     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.4.2.195     Document Type: Review

References (52)

1. Gordon DA, Hastings DE: Clinical features of rheumatoid arthritis. In: Rheumatology. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (Eds): Mosby, PA, USA 765-780 (2003).
2. Alamanos Y, Voulgari PV, Drosos AA: Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology Criteria: a systematic review. Semin. Arthritis Rheum. 36, 182-188 (2006).
3. MacGregor AJ, Silman AJ: Classification and epidemiology In: Rheumatology. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (Eds). Mosby, PA, USA 757-763 (2003).
4. Lockshin MD: Sex differences in autoimmune disease. Lupus 15, 753-756 (2006).
5. Lockshin MD: Genome and hormones: gender differences in physiology. Invited review: sex ratio and rheumatic diseases. J. Appl. Physiol. 91, 2366-2373 (2001).
6. Zandman-Goddard G, Peeva E, Shoenfeld Y: Gender and autoimmunity. Autoimm. Rew. 6, 366-372 (2007).
7. Gregersen PK, Behrens TW: Genetics of autoimmune diseases-disorders of immune homeostasis. Nat. Rev. Genet. 7(12), 917-928 (2006).
8. Petri M, Kim MY, Kai unian KC et al.: OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus. N. Engl. J. Med. 353(21), 2550-2558 (2005).
9. Buyon JP, Petri MA, Kim MY et al.: The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann. Intern. Med. 142(12 Pt 1), 953-962 (2005).
10. Ackerman LS: Sex hormones and the genesis of autoimmunity. Arch. Deramatol. 142, 371-376 (2006).
11. Boumar A, Helneman MJ, Faas M: Sex hormones and the immune response in humans. Hum. Reprod. Update 11, 411-423 (2005).
12. Grimaldi CM: Sex and systemic lupus erythematosus: the role of the sex hormones estrogen and prolactin on the regulation of autoreactive B cells. Curr. Opin Rheumatol. 18(5), 456-461 (2006).
13. Roubinian J,Talal N, Siiteri PK, Sadakian JA: Sex hormone modulation of autoimmunity in NZB/NZW mice. Arthrits Rheum. 22, 1162-1169 (1979).
14. Wilder RL: hormones and autoimmunity: animal models of arthritis. Baillieres Clin. Rheumatol. 10, 259-271 (1996).
15. Cutolo M, Villaggio, B, Craviotto C, Pizzorni C, Seriolo B, Sulli A: Sex hormones and rheumatiod arthritis. Autoimmun. Rev. 1, 284-289 (2002).
16. Tengstrand B, Carlstrom K, Fellander-Tsai L et al.: Abnormal levels of serum dehydroeplandrosterone, estrone, and estradiol in men with rheumatoid arthritis: high correlation between serum estradiol and degree of inflammation. J. Rheumatol. 30, 2338-2343 (2003).
17. Masi AT, Aldac JC, Chatterton R: Sex hormones and risks of rheumatoid arthritis and developmental or environmental influences. Ann. NY Acad. Sci. 1069, 223-235 (2006).
18. Cutolo M, Sulli A, Capellino S et al.: Anti-TNF and sex hormones. Ann. NY Acad Sci. 1069, 391-400 (2006).
19. Tandon VR, Sharma S, Mahajan A, Khajuria V: Pregnancy and rheumatoid arthritis, Indian J. Med. Sci. 60, 334-344 (2006).
20. Hunt JS: Stranger in a strange land. Immunol. Rev. 213, 36-47 (2006).
21. Moffett A, Loke C: Immunology of placentation in eutherian mammals. Nat. Rev. Immunol. 6(8), 584-594 (2006).
22. Chaouat G: The Th1/Th2 paradigm: still important in pregnancy? Semin. Immunopathol. 29(2), 95-113 (2007).
23. Ostensen M, Förger F, Nelson JL, Schumacher A, Hebisch G, Villiger PM: Pregnancy in patients with rheumatic disease: anti-inflammatory cytokines increase in pregnancy and decrease post-partum. Ann. Rheum. Dis. 64, 839-844 (2005).
24. Ostensen M, Villiger PM: The remission of rheumatoid arthritis during pregnancy. Semin. Immunopathol. 29(2), 185-191 (2007).
25. Gerosa M, Riboldi F, Cavazzana I, Thicani A, Meroni PL: Update on pregnancy in autoimmune diseases. Women's Health 3, 417-420 (2007).
26. Ostensen M, Khamashta M, Lockshin M et al.: Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res. Ther. 8(3), 209 (2006).
27. Ostensen M, Motta M: Therapy insight: the use of antirheumatic drugs during nursing. Nat. Clin. Pract. Rheumatol. 3(7), 400-406 (2007).
28. Chambers CD, Jones KL, Johnson DL, Pregnancy outcomes in women exposed to DMARDS agents: the case of leflunomide. Clin. Exp. Rbeumatol. 25, 4, abs L22 (2007).
29. Doran MF, Crowson CS, O'Fallon MW, Gabriel SE: The effect of oral contraceptives and estrogen replacement therapy on the risk of rheumatoid arthritis: a population based study. J. Rheumatol. 31(2), 207-213 (2004).
30. D'Elia HF, Larsen A, Waltbrand E et. al., Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis. Ann., Rheum. Dis. 62, 617-23 (2003).
31. Sinigaglia L, Varenna M, Girasole G, Bianchi G: Epidemiology of osteoporosis in rheumatic diseases. Rheum. Dis. Clin. North. Am. 32(4), 631-658 (2006).
32. Jochems C, Islander U, Erlandsson M, Verdrengh M, Ohlsson C, Carlsten H: Osteoporosis in experimental postmenaopausal polyarthritis: the relative contributions of estrogen deficiency and inflammation. Arth. Res. Ther. 7, R837-R843 (2005).
33. Walsh MC, Kim N, Kadono Y et al.: Osteoimmunology: interplay between the immune system and bone metabolism. Ann. Rev. Immunol. 24, 33-63 (2006).
34. Takayanagi H: Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nature 7, 292-304 (2007).
35. Sato K: Osteoclasts, rheumatoid arthritis and osteoimmunology. Curr. Opin Rheumatol. 18, 419-426 (2006).
36. Gravallese EM, Manning C, Tsay A et al.: Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 43, 250-258 (2000).
37. Takayanagi H, Lizuka H,Juji T et al.: Involvement of receptor activator of nuclear factor kB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis: Arthrins. Rheum. 43(2), 259-269 (2000).
38. Phillips K, Alipranti A,Coblyn J: Strategies for the prevention and treatment of osteoporosis in patients with rheumatoid arthritis. Drugs Aging 23(10), 773-779 (2006):
39. Calrsten H: Immune responses and bone loss: the estrogen connection. Immunol. Rev. 208, 194-206 (2005).
40. Van den Brink HR, Lems WF, van Everdingen AA, Bijlsma JW: Adjuvant oestrogen treatment increases bone mineral density in postmenopausal women with rheumatoid arthritis. Ann. Rheum. Dis. 52(4), 302-305 (1993).
41. Forsblad d'Elia H, Christgau S, Mattsson LA et al.: Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial. Arth. Res. Ther. 6, R457-R468 (2004).
42. Rossouw JE, Anderson GL, Prentice RL et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321-333 (2002).
43. Beral V: Breast cancer and hormone-replacement therapy in the Million Women, Study. Lancet 362, 419-427 (2003).
44. Kaplan MJ: Cardiovascular disease in rheumatoid arthritis. Curr. Opin. Rheumatol. 18(3), 289-297 (2006),
45. Seriolo R, Paolino S, Sulli, A, Ferretti V, Cutolo M: Bone metabolism changes during anti-TNF-α therapy in patients with active rheumatoid arthritis. Ann. NY Acad Sci. 1069, 420-427 (2006).
46. Lange U, Teichmann J, Muller-Ladner U, Strunk J: Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-α antibody: a prospective open-label pilot study. Rheumatolgy 44 (12), 1546-1548 (2005).
47. Vis M, Havaardsholm EA, Haugeberg G et al.: Evaluation of bone mineral density, bone metabolism. osteoprotegerin and receptor activator of the NFkB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 65, 1495-1499 (2006).
48. KJmble RB, Bain S, Pacifici R: The functional block of TNF but not of IL-6 prevents bone loss in ovarectomized mice. J. Bone Min. Res. 12, 935-941 (1997).
49. Lems WE Lockler MC, Lips P et al.: Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. Osteoporosis International 17, 716-723 (2006).
50. Yilmaz L, Ozoran K, Guncluz OH, Ucan H, Yucel M: Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids. Rheumatol. Intl20(2), 65-69 (2001).
51. Roux CH. Brocq O, Breuil V, Albeit C, Euler-Ziegler L: Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-α therapy. Rheumatology (Oxford) 46(4), 695-698 (2007).
52. Sinha A, Patient C: Rheumatoid arthritis in pregnancy: successful outcome with anti-TNF agent (etanercept). J. Obstet Gynaecol. 26(7), 689-691 (2006).